LitAlert ~~ GeneLit.com

    • The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations.
    • Tomiczek-Szwiec J, Szwiec M, Falco M, Cybulski C, Wokolorczyk D, Jakubowska A, Gronwald J, Stawicka M, Godlewski D, Kilar E, Marczyk E, Siolek M, Wisniowski R, Haus O, Sibilski R, Bodnar L, Sun P, Narod SA, Lubinski J, Huzarski T, & the Polish Breast Cancer Consortium.
    • Br J Cancer. 2022 Mar 7. doi: 10.1038/s41416-022-01770-1. Epub ahead of print.
    • The Clinical Utility and Impact of Next Generation Sequencing in Gynecologic Cancers.
    • Maruthi VK, Khazaeli M, Jeyachandran D, Desouki MM.
    • Cancers (Basel). 2022 Mar 7;14(5):1352. doi: 10.3390/cancers14051352.
    • High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer.
    • Wu R, Patel A, Tokumaru Y, Asaoka M, Oshi M, Yan L, Ishikawa T, Takabe K.
    • Breast Cancer Res Treat. 2022 Mar 6. doi: 10.1007/s10549-022-06552-0. Epub ahead of print.
    • Sequencing of BRCA1/2-alterations using NGS-based technology: annotation as a challenge.
    • Ebner S, Winkelmann R, Martin S, Köllermann J, Wild PJ, Demes M.
    • Oncotarget. 2022 Mar 3;13:464-475. doi: 10.18632/oncotarget.28213.
    • February 2022 Editor’s Choice: HRD: What does it really mean and are we looking at this the right way?
    • Huh WK, Swisher E, Ledermann JA.
    • Gynecol Oncol. 2022 Feb. Podcasts.

    Original research:

    Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.

    Commentary:

    Testing for homologous recombination deficiency - does it provide new insights for the use of veliparib?